Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas

British Journal of Haematology(2024)10.1111/bjh.19419Source: DataRank Database

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas is a research paper published in British Journal of Haematology (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 1.44)OA: bronzeTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Catherine Diefenbach ORCID,Deepa Jagadeesh ORCID,Adam Asch,Abhijeet Kumar ORCID,Michaela L. Tsai

Live enrichment

PubMed:38500476 PMC:PMC11156518 OpenAlex:https://openalex.org/W4392970713

Memorial Sloan-Kettering Cancer Center

Grant: P30‐5P30CA008748‐55

Memorial Sloan-Kettering Cancer Center

Grant: P50‐5P50CA192937‐05

National Cancer Institute

Grant: K08CA270202‐01

NCI NIH HHS

Grant: K08 CA270202

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: K08CA270202-01

NCI NIH HHS

Grant: P50 CA192937

MEI Pharma

Lymphoma Research Foundation

BeiGene

Lymphoma Research Foundation

FWCI

1.44

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.19419

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.19419

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19419

journalhttps://doi.org/10.1111/bjh.19419

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38500476

Fields of Study

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentViral-associated cancers and disordersHumansLymphoma, Mantle-CellFemaleMaleAgedMiddle AgedLymphoma, FollicularPyrimidinesPyrazolesAntineoplastic Combined Chemotherapy ProtocolsAdultThiazolesAged, 80 and overAgammaglobulinaemia Tyrosine KinaseTreatment OutcomePiperidines

MeSH Terms

Agammaglobulinaemia Tyrosine KinaseAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansLymphoma, FollicularMaleMiddle AgedPiperidinesPyrazolesPyrimidinesThiazolesTreatment OutcomeLymphoma, Mantle-Cell

Keywords

MedicineMantle cell lymphomaCancer researchOncologyInternal medicinePathologyLymphomaClinical TrialFollicular LymphomaZanubrutinibZandelisib

Sustainable Development Goals

SDG 0: Good health and well-being

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas

FAIR Checklist

Authors (16)

Funding (11 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)